Ad Code: Ibtrozi - Display Banners Conference - AUG - 231762

Analyses suggest squamous and nonsquamous tumors differ in immunobiology and may respond differently to the addition of LAG-3 inhibitors to PD-1–based therapy.

A new complete blood count-based score predicted worse outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.

Tailored radiotherapy with nonuniform target compromises and stringent constraints delivered excellent local control and low toxicity for ultra‑central NSCLC.

Nearly 1 in 5 patients with NSCLC and targetable mutations never received second‑line therapy, highlighting the urgency of optimizing first‑line treatments.